Search Result

Results for "

Stearoyl-CoA Desaturase (SCD)

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Stearoyl-CoA Desaturase (SCD) (23) Apoptosis (2) Autophagy (1) Bacterial (2) DNA/RNA Synthesis (1) Endogenous Metabolite (1) Fatty Acid Synthase (FASN) (2) Glutathione Peroxidase (1) Influenza Virus (3) Interleukin Related (1) LDLR (1) mTOR (1) Reactive Oxygen Species (ROS) (1) Reference Standards (2) SOD (1) TNF Receptor (1)
By Research Areas:	Cancer (10) Infection (2) Inflammation/Immunology (3) Metabolic Disease (13) Neurological Disease (1)

Inhibitors & Agonists

Screening Libraries

Natural
Products

Recombinant Proteins

Targets Recommended: Stearoyl-CoA Desaturase (SCD) Dihydroceramide Desaturase 1 (DES1)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-50709

A939572 Maximum Cited Publications 40 Publications Verification	Stearoyl-CoA Desaturase (SCD)	Cancer
A939572 is a potent, and orally bioavailable **stearoyl-CoA desaturase1 (SCD1) inhibitor with IC₅₀ values of <4 nM and 37 nM for mSCD1 and hSCD1**, respectively.

HY-15823

CAY10566 15+ Cited Publications	Stearoyl-CoA Desaturase (SCD)	Cancer
CAY10566 is a potent, orally bioavailable and selective **stearoyl-CoA desaturase1** (SCD1) inhibitor with IC₅₀s of 4.5 and 26 nM in mouse and human enzymatic assays, respectively. CAY10566 also shows excellent cellular activity in blocking the conversion of saturated long-chain fatty acid-CoAs (LCFA-CoAs) to monounsaturated LCFA-CoAs in HepG2 cells (IC₅₀=7.9 nM or 6.8 nM) .

HY-15700

PluriSIn 1 4 Publications Verification NSC 14613	Stearoyl-CoA Desaturase (SCD) Apoptosis	Cancer
PluriSIn 1 (NSC 14613) is an inhibitor of stearoyl-coA desaturase (SCD), and is a pluripotent cell-specific inhibitor.

HY-155033

SSI-4	Stearoyl-CoA Desaturase (SCD) DNA/RNA Synthesis Apoptosis Autophagy mTOR Influenza Virus	Metabolic Disease Inflammation/Immunology Cancer
SSI-4 is an orally active stearoyl-CoA desaturase (SCD1) inhibitor with an EC₅₀ of 1.9 nM against mouse SCD1. SSI-4 blocks the conversion of saturated fatty acids to monounsaturated fatty acids, reducing the production of oleic acid and palmitoleic acid. SSI-4 induces lipid peroxidation, endoplasmic reticulum stress, DNA damage and activates apoptotic mechanisms. SSI-4 inhibits mTORC1 activity, suppresses B cell proliferation and antibody production, and induces autophagy. SSI-4 is applicable to research on cancers such as acute myeloid leukemia and renal cell carcinoma, as well as influenza infections .

HY-19762

GSK1940029 3 Publications Verification SCD inhibitor 1	Stearoyl-CoA Desaturase (SCD)	Cancer
GSK1940029 (SCD inhibitor 1) is a stearoyl-coa desaturase (SCD) inhibitor extracted from patent WO/2009060053 A1, compound example 16.

HY-13070

MK-8245 4 Publications Verification	Stearoyl-CoA Desaturase (SCD)	Metabolic Disease
MK-8245 is a potent, liver-targeted **stearoyl-CoA desaturase (SCD) inhibitor, with IC₅₀*s of 1 nM for human SCD1 and 3 nM for both rat SCD1 and mouse SCD*1, with antidiabetic and antidyslipidemic efficacy .

HY-15822

MF-438 5+ Cited Publications	Stearoyl-CoA Desaturase (SCD)	Metabolic Disease
MF-438 is a potent and orally bioavailable **stearoyl-CoA desaturase 1 (SCD1) inhibitor with an IC₅₀** of 2.3 nM for rSCD1 .

HY-127143

Sterculic acid	Stearoyl-CoA Desaturase (SCD)	Inflammation/Immunology
Sterculic acid is a stearoyl-CoA desaturase-1 (SCD1) inhibitor. Sterculic acid specifically inhibits the delta-9 desaturase (Δ9D) activity with an IC₅₀ value of 0.9 μM .

HY-N6807

Elemicin 1 Publications Verification	Stearoyl-CoA Desaturase (SCD) Influenza Virus Bacterial	Infection Cancer
Elemicin is an orally active alkenylbenzene widely distributed in many herbs and spices. Elemicin inhibits **Stearoyl-CoA Desaturase 1 (SCD1) by metabolic activation. Elemicin has anti-influenza activities, antimicrobial, antioxidant, and antiviral** activities. Elemicin and its reactive metabolite of 1′-Hydroxyelemicin can induce hepatotoxicity .

HY-141525

SCD1 inhibitor-4	Stearoyl-CoA Desaturase (SCD)	Metabolic Disease
SCD1 inhibitor-4 is a potent, orally active stearoylCoA desaturase-1 (SCD1) inhibitor. SCD1 inhibitor-4 can be used for the research of diabetes .

HY-124346

T-3364366 1 Publications Verification	Stearoyl-CoA Desaturase (SCD)	Metabolic Disease
T-3364366 is a reversible, slow-binding, thienopyrimidinone delta-5 desaturase (D5D) inhibitor with IC₅₀s of 1.9 nM and 2.1 nM in HepG2 and RLN-10 cells, respectively. T-3364366 exhibits potent D5D (IC₅₀0=19 nM) inhibitory activity and excellent selectivity away from delta-6 desaturase (D6D, IC₅₀=6200 nM) and delta-9 desaturase (stearoyl-CoA desaturase, SCD,₅₀ >10000 nM) in the enzymatic activity assay .

HY-112812

SCD1 inhibitor-1	Stearoyl-CoA Desaturase (SCD)	Metabolic Disease
SCD1 inhibitor-1 (Compound 48) is an orally active and liver-selective inhibitor of stearoyl-CoA desaturase 1 (SCD1) with an IC₅₀ of 8.8 nM for recombinant human SCD1 enzyme. SCD1 inhibitor-1 can be used in the study of diseases such as diabetes, hepatic steatosis and obesity .

HY-13077

MK-8245 Trifluoroacetate 4 Publications Verification	Stearoyl-CoA Desaturase (SCD)	Metabolic Disease
MK-8245 trifluoroacetate is a liver-targeting inhibitor of stearoyl-CoA desaturase (SCD) with IC50 of 1 nM for human SCD1 and 3 nM for both rat SCD1 and mouse SCD1, with anti-diabetic and anti-dyslipidemic efficacy.

HY-100249

XEN723	Stearoyl-CoA Desaturase (SCD)	Metabolic Disease
XEN723 is a novel and potent thiazolylimidazolidinone inhibitor of **Stearoyl-CoA Desaturase** (SCD1) with IC₅₀s of 45 and 524 nM in mouse and HepG2 cell, respectively.

HY-E70265

18:0 Coenzyme A triammonium	Fatty Acid Synthase (FASN) Endogenous Metabolite	Metabolic Disease
18:0 Coenzyme A (triammonium) is a preferred substrate of stearoyl-CoA desaturases (SCDs) .

HY-11034

CVT-12012	Stearoyl-CoA Desaturase (SCD)	Metabolic Disease
CVT-12012 is a potent and orally bioavailable stearoyl-coA desaturase *(SCD)* inhibitor, with IC₅₀s of 38 nM, 6.1 nM for rat microsomal and human HEPG2, respectively.

HY-124084

SW203668	Stearoyl-CoA Desaturase (SCD)	Cancer
SW203668 is an irreversible **stearoyl CoA desaturase (SCD) inhibitor with an IC₅₀** of 54 nM. SW203668 covalently binds and inhibits SCD, depletes unsaturated fatty acids, and triggers cell death in sensitive cells. SW203668 requires demethylation by CYP4F11 to form its active SCD-inhibiting form; differential CYP4F11 expression drives selective cytotoxicity. SW203668 exerts cytotoxicity toward CYP4F11-expressing non-small cell lung cancer (NSCLC) cells and spares CYP4F11-lacking NSCLC cells. SW203668 inhibits tumor growth in immunodeficient mice bearing CYP4F11-expressing NSCLC xenografts and spares mouse skin sebocytes. SW203668 can be used for the research of non-small cell lung cancer .

HY-124751

YTX-465	Stearoyl-CoA Desaturase (SCD)	Neurological Disease
YTX-465 is a **stearoyl-CoA desaturase (Ole1/SCD)** inhibitor. YTX-465 inhibits Ole1 and SCD1 with IC₅₀s of 0.039 μM and 30.4 μM, respectively. YTX-465 can be used in the research of Parkinson’s disease and other synucleinopathies .

HY-176274

FASN/SCD-IN-1	Fatty Acid Synthase (FASN) Stearoyl-CoA Desaturase (SCD) Reactive Oxygen Species (ROS) Interleukin Related TNF Receptor SOD LDLR Glutathione Peroxidase	Metabolic Disease Inflammation/Immunology
FASN/SCD-IN-1 is a Silybin (HY-N0779A) derivative, an orally active inhibitor of Fatty Acid Synthase (FASN)/Stearoyl-CoA *Desaturase* (SCD). FASN/SCD-IN-1 has shown in vitro activity in inhibiting lipid deposition, reducing FASN and *SCD* transcriptional levels, and exhibiting antioxidant, anti-inflammatory, and anti-fibrotic activities. FASN/SCD-IN-1 has demonstrated significant hepatoprotective effects in a rat model of acute liver injury. FASN/SCD-IN-1 ameliorates the pathological features of MASH liver, including steatosis, inflammation, and fibrosis in a mouse model of myeloproliferative steatohepatitis (MASH). FASN/SCD-IN-1 can be used to study MASH .

HY-50709R

A939572 (Standard)	Stearoyl-CoA Desaturase (SCD)	Cancer
A939572 (Standard) is the analytical standard of A939572. This product is intended for research and analytical applications. A939572 is a potent, and orally bioavailable stearoyl-CoA desaturase1 (SCD1) inhibitor with IC50 values of <4 nM and 37 nM for mSCD1 and hSCD1, respectively.

HY-N6807R

Elemicin (Standard)	Reference Standards Stearoyl-CoA Desaturase (SCD) Influenza Virus Bacterial	Infection Cancer
Elemicin is an orally active alkenylbenzene widely distributed in many herbs and spices. Elemicin inhibits Stearoyl-CoA Desaturase 1 (SCD1) by metabolic activation. Elemicin has anti-influenza activities, antimicrobial, antioxidant, and antiviral activities. Elemicin and its reactive metabolite of 1′-Hydroxyelemicin can induce hepatotoxicity .

HY-114184

MK-8245 analog	Stearoyl-CoA Desaturase (SCD)	Metabolic Disease
MK-8245 analog (compound 6) is a potent **stearoyl-CoA desaturase (SCD) inhibitor with an IC₅₀** of 7 nM for rat SCD. MK-8245 analog has antidiabetic and antidyslipidemic effects .

HY-124084A

SW203668 TFA	Stearoyl-CoA Desaturase (SCD)	Cancer
SW203668 TFA is an irreversible **stearoyl CoA desaturase (SCD) inhibitor with an IC₅₀** of 54 nM. SW203668 TFA covalently binds and inhibits SCD, depletes unsaturated fatty acids, and triggers cell death in sensitive cells. SW203668 TFA requires demethylation by CYP4F11 to form its active SCD-inhibiting form; differential CYP4F11 expression drives selective cytotoxicity. SW203668 TFA exerts cytotoxicity toward CYP4F11-expressing non-small cell lung cancer (NSCLC) cells and spares CYP4F11-lacking NSCLC cells. SW203668 TFA inhibits tumor growth in immunodeficient mice bearing CYP4F11-expressing NSCLC xenografts and spares mouse skin sebocytes. SW203668 TFA can be used for the research of non-small cell lung cancer .

HY-100249R

XEN723 (Standard)	Stearoyl-CoA Desaturase (SCD) Reference Standards	Metabolic Disease
XEN723 (Standard) is the analytical standard of XEN723 (HY-100249). This product is intended for research and analytical applications. XEN723 is a novel and potent thiazolylimidazolidinone inhibitor of Stearoyl-CoA Desaturase (SCD1) with IC50s of 45 and 524 nM in mouse and HepG2 cell, respectively.

Cat. No.	Product Name

HY-L087

Anti-Obesity Compound Library	3,558 compounds
Obesity is widely recognized as the largest and fastest growing public health problem and is associated with numerous chronic disorders including osteoarthritis, obstructive sleep apnea, gallstones, fatty liver disease, reproductive and gastrointestinal cancers, dyslipidemia, hypertension, type 2 diabetes, heart failure, coronary artery disease, stroke, etc. Although obesity has long been associated with serious health issues, it has only recently been regarded as a disease in the sense of being a specific target for medical therapy. Obesity may be viewed as the dysregulation of two physiological functions, appetite regulation and energy metabolism, which combine to create disordered energy balance. Consequently, developing obesity treatments that target novel pathways is a growing focus for both biopharmaceutical industries. MCE Anti-Obesity Compound Library owns a unique collection of 3,558 compounds, which mainly target signaling pathway of controlling appetite, fatty acid metabolism and energy expenditure, etc. This library is a useful tool for discovery anti-obesity drugs.

Anti-Obesity Compound Library

3,558 compounds

Obesity is widely recognized as the largest and fastest growing public health problem and is associated with numerous chronic disorders including osteoarthritis, obstructive sleep apnea, gallstones, fatty liver disease, reproductive and gastrointestinal cancers, dyslipidemia, hypertension, type 2 diabetes, heart failure, coronary artery disease, stroke, etc. Although obesity has long been associated with serious health issues, it has only recently been regarded as a disease in the sense of being a specific target for medical therapy. Obesity may be viewed as the dysregulation of two physiological functions, appetite regulation and energy metabolism, which combine to create disordered energy balance. Consequently, developing obesity treatments that target novel pathways is a growing focus for both biopharmaceutical industries.

MCE Anti-Obesity Compound Library owns a unique collection of 3,558 compounds, which mainly target signaling pathway of controlling appetite, fatty acid metabolism and energy expenditure, etc. This library is a useful tool for discovery anti-obesity drugs.

Sterculic acid	Classification of Application Fields Ketones, Aldehydes, Acids Sterculiaceae Plants Inflammation/Immunology Disease Research Fields Sterculia foetida Linn. Source Classification	Stearoyl-CoA Desaturase (SCD)
Sterculic acid is a stearoyl-CoA desaturase-1 (SCD1) inhibitor. Sterculic acid specifically inhibits the delta-9 desaturase (Δ9D) activity with an IC₅₀ value of 0.9 μM .

Elemicin 1 Publications Verification	Infection Asarum sieboldii Miq. Classification of Application Fields Simple Phenylpropanols Phenylpropanoids Plants Disease Research Fields Aristolochiaceae Source Classification	Stearoyl-CoA Desaturase (SCD) Influenza Virus Bacterial
Elemicin is an orally active alkenylbenzene widely distributed in many herbs and spices. Elemicin inhibits **Stearoyl-CoA Desaturase 1 (SCD1) by metabolic activation. Elemicin has anti-influenza activities, antimicrobial, antioxidant, and antiviral** activities. Elemicin and its reactive metabolite of 1′-Hydroxyelemicin can induce hepatotoxicity .

Elemicin (Standard)	Asarum sieboldii Miq. Structural Classification Simple Phenylpropanols Phenylpropanoids Plants Aristolochiaceae Source Classification	Reference Standards Stearoyl-CoA Desaturase (SCD) Influenza Virus Bacterial
Elemicin is an orally active alkenylbenzene widely distributed in many herbs and spices. Elemicin inhibits Stearoyl-CoA Desaturase 1 (SCD1) by metabolic activation. Elemicin has anti-influenza activities, antimicrobial, antioxidant, and antiviral activities. Elemicin and its reactive metabolite of 1′-Hydroxyelemicin can induce hepatotoxicity .

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P702428

	SCD Protein, Human (Cell-Free, His) Stearoyl-CoA Desaturase; Acyl-CoA Desaturase; Delta(9)-Desaturase; Delta-9 Desaturase; Fatty acid Desaturase; FADS5; SCD1; SCDOS	Human	E. coli Cell-free
	SCD proteins (or stearoyl-CoA desaturases) critically catalyze the introduction of the first double bond into saturated fatty acyl-CoA substrates (such as palmitoyl-CoA and stearoyl-CoA). This process produces a mixture of 16:1 and 18:1 unsaturated fatty acids, which play a crucial role in lipid biosynthesis. SCD Protein, Human (Cell-Free, His) is the recombinant human-derived SCD protein, expressed by E. coli Cell-free , with N-10*His labeled tag. The total length of SCD Protein, Human (Cell-Free, His) is 359 a.a., with molecular weight of 44.3 kDa.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks